AEON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aeon Biopharma Inc (AEON) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock's technical indicators show a bearish trend, and the company's financial performance is weak with significant losses. While there is some positive news about FDA feedback on its ABP-450 product, the lack of significant trading trends, no recent congress trading data, and no proprietary trading signals suggest that this is not an optimal entry point for investment.
The MACD is negative and expanding, indicating a bearish trend. RSI is at 28.432, suggesting the stock is nearing oversold territory but not yet a clear buy signal. Moving averages are converging, showing no strong trend. The stock is trading near its S1 support level of 1.006, with further downside potential to S2 at 0.944.
AEON received supportive feedback from the FDA regarding its ABP-450 biosimilar to Botox, and the company plans to advance its analytical comparability program in 2026.
The stock has a 66.67% chance of declining in the short term (-2.2% next day, -5.03% next week). Financial performance is weak, with significant net income and EPS declines. No significant trading trends from hedge funds or insiders.
In Q3 2025, AEON reported zero revenue growth (0.00% YoY) and a net income loss of -$4.54M, down -26.46% YoY. EPS dropped significantly by -96.53% YoY to -0.39. Gross margin remains at 0 with no improvement.
No analyst rating or price target changes available.
